BIIB : Summary for Biogen Inc. - Yahoo Finance

U.S. Markets open in 3 hrs 25 mins

Biogen Inc. (BIIB)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
288.94-1.19 (-0.41%)
At close: 4:00PM EST
People also watch
CELGGILDREGNAMGNALXN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close290.13
Open290.00
Bid288.60 x 100
Ask289.00 x 900
Day's Range287.76 - 291.90
52 Week Range223.02 - 333.65
Volume1,770,399
Avg. Volume1,860,354
Market Cap62.4B
Beta0.50
PE Ratio (TTM)17.07
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands?
    Motley Fool18 hours ago

    Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands?

    A big phase 3 win for its up-and-coming multiple sclerosis drug could clear the path to billions of dollars in additional annual sales for this big-cap biotech stock.

  • American City Business Journals3 days ago

    ​Shkreli defends drug prices, spars with protesters at heated UMass Boston event

    Controversial pharmaceutical executive Martin Shkreli used a speaking appearance at UMass Boston on Thursday to defend the high cost of some rare disease treatments, including a drug developed by Cambridge-based Biogen. The talk came one day after Shkreli gave a similar address at Harvard University. During Thursday’s event, Shkreli verbally sparred with some attendees over his company’s decision to buy Daraprim, a treatment for a parasitic infection, and raise the price from $13.50 per pill to $750.

  • American City Business Journals3 days ago

    Tesaro sees a $5B market opportunity for its cancer drug

    The CEO of Tesaro said Thursday that the market size for one of the Waltham company's cancer treatments could eventually surpass the $5 billion mark if approved, potentially placing it in one of the biggest drug markets in any biotech based in Massachusetts. CEO Lonnie Moulder made the eye-popping projection for niraparib during a presentation at Leerink Partners' annual global healthcare conference, according to a webcast of the event. Tesaro’s projection for niraparib is based on estimates that there is a $4 billion annual market opportunity in the U.S. and E.U. for the treatment of ovarian cancer, plus $1 billion in breast cancer.